No­vo Nordisk scores a win for semaglu­tide in obe­si­ty, po­ten­tial­ly set­ting up a next-gen bat­tle with Eli Lil­ly

No­vo Nordisk pulled a high­ly an­tic­i­pat­ed win for its GLP-1 ther­a­py semaglu­tide in obe­si­ty on Fri­day, be­com­ing the first com­pa­ny to get a chron­ic weight …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.